MBOT is a medical device company focused on transforming endovascular procedures through advanced robotic technology. Endovascular procedures are minimally invasive interventions performed inside blood vessels using catheters and guidewires. I follow the company primarily because of its LIBERTY robotic platform, which aims to make these procedures safer and more accessible by allowing physicians to operate remotely while reducing radiation exposure and physical strain. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Microbot Medical was founded in 2010 and is headquartered in Hingham, Massachusetts. The company researches, designs, and develops robotic endoluminal surgery devices targeting the minimally invasive surgery space, a segment of healthcare where tools are inserted into the body through natural openings or small incisions rather than large surgical cuts.
The company's core product is the LIBERTY Endovascular Robotic System. According to the company, LIBERTY is a single-use, remotely operated robotic system designed to maneuver guidewires and other over-the-wire devices, such as microcatheters, within the body's vasculature. It is positioned for use across cardiovascular, peripheral, endovascular, and neurovascular operations, and the company highlights the system's potential to reduce physician radiation exposure and physical strain during catheter-based procedures.
Microbot Medical's business model centers on developing and commercializing proprietary robotic platforms and associated single-use consumables. The company's revenue model is expected to be driven by the sale of LIBERTY systems and related disposables to hospitals, health systems, and physicians. The company also holds NovaCross, an intellectual property asset and technology in the field of intraluminal revascularization devices with an anchoring mechanism and integrated microcatheter.
The company has historically operated as a single reporting segment focused on the development of robotic devices for endoluminal surgery. As a relatively young commercial-stage business, its financial profile is characterized by modest early revenue and ongoing operating losses, which is common for medical device companies investing heavily in regulatory clearance, clinical validation, and commercialization before reaching scale.
In terms of market position, Microbot Medical competes in the emerging field of endovascular and vascular robotics, an area that also includes larger, more established medical technology firms. The company's competitive positioning emphasizes the single-use, remotely operated, and compact design of LIBERTY as a differentiating feature, alongside a growing intellectual property portfolio.
Investors follow MBOT because it operates at the intersection of two long-term healthcare trends: the shift toward minimally invasive procedures and the increasing adoption of robotics in medicine. The company's LIBERTY platform is designed to make robotic-assisted vascular intervention more portable and cost-effective, potentially lowering barriers to adoption for hospitals and outpatient labs. From what I see, the long-term growth narrative rests on several factors. First, its regulatory milestones, including FDA clearance for the LIBERTY system, represent critical validation of the technology. Second, the company points to a sizable addressable market in peripheral endovascular procedures in the United States. Third, collaborations with academic and healthcare institutions, such as Corewell Health and Emory University, support continued product development and, in the case of Emory University, research into autonomous robotics in endovascular procedures.
Investors also watch the company's commercialization progress, including customer adoption, procedure utilization, and the expansion of its sales territories, as indicators of whether the technology can transition from an early-stage innovation to a commercially viable product line.
Investing in MBOT carries meaningful risks. As a commercial-stage medical device company with limited revenue, Microbot Medical continues to report operating losses and negative gross margins during its early commercialization phase, and it may require additional capital to fund ongoing operations and growth. The company's financial profile is not yet profitable, and its valuation reflects expectations about future adoption rather than current earnings.
The company also faces significant competition from larger, well-capitalized medical technology companies in the vascular and surgical robotics markets. Technological disruption, the pace of physician adoption, and the complexity of hospital purchasing and approval processes can all affect how quickly a new device gains traction.
Regulatory risk is another key consideration. Medical device companies depend on obtaining and maintaining clearances from bodies such as the U.S. Food and Drug Administration (FDA), and any delays, denials, or post-market requirements could affect commercialization. Macroeconomic sensitivity in healthcare spending, reimbursement decisions, and the company's relatively small scale and early customer base add further uncertainty. As with all investments, these factors should be carefully weighed.
In my analysis, I frequently rely on Tickeron’s AI Screener to cross-reference technical signals and industry comparisons for names like MBOT. This helps me quickly filter opportunities and validate patterns without sifting through raw data manually. It has become a practical part of my workflow for staying on top of emerging medical technology plays.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
MBOT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 36 cases where MBOT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MBOT's RSI Indicator exited the oversold zone, 23 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for MBOT just turned positive on October 22, 2026. Looking at past instances where MBOT's MACD turned positive, the stock continued to rise in 37 of 48 cases over the following month. The odds of a continued upward trend are 77%.
Following a +9.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBOT advanced for three days, in 150 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBOT as a result. In 76 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBOT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for MBOT entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. MBOT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.082) is normal, around the industry mean (4.142). P/E Ratio (-4.440) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (263.158) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBOT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which specializes in the research, design, development and commercialization of micro-robotics assisted medical technologies
Industry MedicalNursingServices